Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Low cost of generic medicines is a significant driver for demand, as their efficacy is at par with branded medicines

    60% confidence
  • The global Generic Drug Market will grow at a CAGR of approximately 6.55% during the forecast period from 2025 to 2034

    60% confidence
  • The global Generic Drug Market is expected to reach USD 519.11 Billion in 2025

    60% confidence
  • Asia Pacific is the second-largest market for generic medicines, driven by low disposable income and high chronic disease burden

    60% confidence
  • Oncology has emerged as the largest therapeutic application segment for generic medicines due to high global cancer prevalence

    60% confidence
  • Pure generic drugs experienced tremendous market growth due to high consumer demand and advanced manufacturing technologies

    60% confidence
  • North America is the largest regional market for generic drugs, driven by a large geriatric population with chronic diseases and the presence of key market players

    60% confidence
  • Expanding generic drug store presence in rural sectors represents a significant growth opportunity for the market

    60% confidence
  • Retail pharmacies are the largest distribution channel for generic drugs due to direct access to consumers

    60% confidence
  • Oral formulations are the leading route of administration for generic drugs and the most commonly used, including for children

    60% confidence
  • The global Generic Drug Market size was valued at approximately USD 491.35 Billion in 2024

    60% confidence
  • The global Generic Drug Market is projected to reach approximately USD 926.54 Billion by 2034

    60% confidence
  • Private medical practitioners preferring branded medicines due to higher profit margins is a key market restraint

    60% confidence
  • Lack of awareness about generic drug efficacy and absence of generic drug stores in rural areas are major market restraints

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com